Cerebrospinal fluid cholinesterases in aging and in dementia of the Alzheimer type

J. R. Atack, C. May, Jeffrey Kaye, A. D. Kay, S. I. Rapoport

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

Protein concentration and acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) activities were assayed in the cerebrospinal fluid (CSF) of 26 healthy normal subjects (20-86 years old), 27 patients with dementia of the Alzheimer type (DAT), and 10 patients with dementia of the Alzheimer type with extrapyramidal signs (EDAT). In normal subjects, there was an age-related increase in CSF protein and AChE activity and a significant correlation (p <0.001) between CSF protein and BChE activity. In the DAT and EDAT groups, CSF AChE activities (mean ± SD = 17.5 ± 3.6 and 15.3 ± 4.4 nmol/min/ml, respectively) were significantly lower (p <0.05) than in 13 age-matched control subjects (21.5 ± 5.6 nmol/min/ml). In contrast, neither CSF protein concentration, BChE activity, nor the ratio of AChE/BChE differed significantly between groups. In patients with DAT, CSF AChE activity was significantly lower (p <0.05) in subjects with an early onset compared to those with a late onset (16.4 ± 3.4 and 19.7 ± 2.8 nmol/min/ml, respectively), and activity in the latter group did not differ significantly from control values. CSF AChE activity was not related to dementia severity and did not change significantly over an 18-month period. Although these results confirm a cholinergic deficit in patients with DAT, the considerable overlap of CSF AChE activity between groups and the nonsignificant correlation between AChE activity and dementia severity limit the usefulness of CSF AChE as a diagnostic marker of this disorder.

Original languageEnglish (US)
Pages (from-to)161-167
Number of pages7
JournalAnnals of Neurology
Volume23
Issue number2
StatePublished - 1988
Externally publishedYes

Fingerprint

Cholinesterases
Acetylcholinesterase
Cerebrospinal Fluid
Alzheimer Disease
Butyrylcholinesterase
Cerebrospinal Fluid Proteins
Dementia
Cholinergic Agents
Healthy Volunteers

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Atack, J. R., May, C., Kaye, J., Kay, A. D., & Rapoport, S. I. (1988). Cerebrospinal fluid cholinesterases in aging and in dementia of the Alzheimer type. Annals of Neurology, 23(2), 161-167.

Cerebrospinal fluid cholinesterases in aging and in dementia of the Alzheimer type. / Atack, J. R.; May, C.; Kaye, Jeffrey; Kay, A. D.; Rapoport, S. I.

In: Annals of Neurology, Vol. 23, No. 2, 1988, p. 161-167.

Research output: Contribution to journalArticle

Atack, JR, May, C, Kaye, J, Kay, AD & Rapoport, SI 1988, 'Cerebrospinal fluid cholinesterases in aging and in dementia of the Alzheimer type', Annals of Neurology, vol. 23, no. 2, pp. 161-167.
Atack, J. R. ; May, C. ; Kaye, Jeffrey ; Kay, A. D. ; Rapoport, S. I. / Cerebrospinal fluid cholinesterases in aging and in dementia of the Alzheimer type. In: Annals of Neurology. 1988 ; Vol. 23, No. 2. pp. 161-167.
@article{44e073ffc5d442feab30b46b3cf6ac13,
title = "Cerebrospinal fluid cholinesterases in aging and in dementia of the Alzheimer type",
abstract = "Protein concentration and acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) activities were assayed in the cerebrospinal fluid (CSF) of 26 healthy normal subjects (20-86 years old), 27 patients with dementia of the Alzheimer type (DAT), and 10 patients with dementia of the Alzheimer type with extrapyramidal signs (EDAT). In normal subjects, there was an age-related increase in CSF protein and AChE activity and a significant correlation (p <0.001) between CSF protein and BChE activity. In the DAT and EDAT groups, CSF AChE activities (mean ± SD = 17.5 ± 3.6 and 15.3 ± 4.4 nmol/min/ml, respectively) were significantly lower (p <0.05) than in 13 age-matched control subjects (21.5 ± 5.6 nmol/min/ml). In contrast, neither CSF protein concentration, BChE activity, nor the ratio of AChE/BChE differed significantly between groups. In patients with DAT, CSF AChE activity was significantly lower (p <0.05) in subjects with an early onset compared to those with a late onset (16.4 ± 3.4 and 19.7 ± 2.8 nmol/min/ml, respectively), and activity in the latter group did not differ significantly from control values. CSF AChE activity was not related to dementia severity and did not change significantly over an 18-month period. Although these results confirm a cholinergic deficit in patients with DAT, the considerable overlap of CSF AChE activity between groups and the nonsignificant correlation between AChE activity and dementia severity limit the usefulness of CSF AChE as a diagnostic marker of this disorder.",
author = "Atack, {J. R.} and C. May and Jeffrey Kaye and Kay, {A. D.} and Rapoport, {S. I.}",
year = "1988",
language = "English (US)",
volume = "23",
pages = "161--167",
journal = "Annals of Neurology",
issn = "0364-5134",
publisher = "John Wiley and Sons Inc.",
number = "2",

}

TY - JOUR

T1 - Cerebrospinal fluid cholinesterases in aging and in dementia of the Alzheimer type

AU - Atack, J. R.

AU - May, C.

AU - Kaye, Jeffrey

AU - Kay, A. D.

AU - Rapoport, S. I.

PY - 1988

Y1 - 1988

N2 - Protein concentration and acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) activities were assayed in the cerebrospinal fluid (CSF) of 26 healthy normal subjects (20-86 years old), 27 patients with dementia of the Alzheimer type (DAT), and 10 patients with dementia of the Alzheimer type with extrapyramidal signs (EDAT). In normal subjects, there was an age-related increase in CSF protein and AChE activity and a significant correlation (p <0.001) between CSF protein and BChE activity. In the DAT and EDAT groups, CSF AChE activities (mean ± SD = 17.5 ± 3.6 and 15.3 ± 4.4 nmol/min/ml, respectively) were significantly lower (p <0.05) than in 13 age-matched control subjects (21.5 ± 5.6 nmol/min/ml). In contrast, neither CSF protein concentration, BChE activity, nor the ratio of AChE/BChE differed significantly between groups. In patients with DAT, CSF AChE activity was significantly lower (p <0.05) in subjects with an early onset compared to those with a late onset (16.4 ± 3.4 and 19.7 ± 2.8 nmol/min/ml, respectively), and activity in the latter group did not differ significantly from control values. CSF AChE activity was not related to dementia severity and did not change significantly over an 18-month period. Although these results confirm a cholinergic deficit in patients with DAT, the considerable overlap of CSF AChE activity between groups and the nonsignificant correlation between AChE activity and dementia severity limit the usefulness of CSF AChE as a diagnostic marker of this disorder.

AB - Protein concentration and acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) activities were assayed in the cerebrospinal fluid (CSF) of 26 healthy normal subjects (20-86 years old), 27 patients with dementia of the Alzheimer type (DAT), and 10 patients with dementia of the Alzheimer type with extrapyramidal signs (EDAT). In normal subjects, there was an age-related increase in CSF protein and AChE activity and a significant correlation (p <0.001) between CSF protein and BChE activity. In the DAT and EDAT groups, CSF AChE activities (mean ± SD = 17.5 ± 3.6 and 15.3 ± 4.4 nmol/min/ml, respectively) were significantly lower (p <0.05) than in 13 age-matched control subjects (21.5 ± 5.6 nmol/min/ml). In contrast, neither CSF protein concentration, BChE activity, nor the ratio of AChE/BChE differed significantly between groups. In patients with DAT, CSF AChE activity was significantly lower (p <0.05) in subjects with an early onset compared to those with a late onset (16.4 ± 3.4 and 19.7 ± 2.8 nmol/min/ml, respectively), and activity in the latter group did not differ significantly from control values. CSF AChE activity was not related to dementia severity and did not change significantly over an 18-month period. Although these results confirm a cholinergic deficit in patients with DAT, the considerable overlap of CSF AChE activity between groups and the nonsignificant correlation between AChE activity and dementia severity limit the usefulness of CSF AChE as a diagnostic marker of this disorder.

UR - http://www.scopus.com/inward/record.url?scp=0023876501&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023876501&partnerID=8YFLogxK

M3 - Article

C2 - 3377438

AN - SCOPUS:0023876501

VL - 23

SP - 161

EP - 167

JO - Annals of Neurology

JF - Annals of Neurology

SN - 0364-5134

IS - 2

ER -